Xencor | XNCR - Interest Expense On Debt



Xencor reported 8.24M in Interest Expense on Debt for its fiscal quarter ending in June of 2025.


Interest Expense On Debt Change Date
AbbVie USD 700M 90M Mar/2025
Alnylam Pharmaceuticals USD 40.25M 1.6M Jun/2025
Amgen USD 694M 29M Jun/2025
Arrowhead Research USD 24.38M 2.74M Jun/2025
AstraZeneca 303M 126M Jun/2025
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 485M 9M Jun/2025
Cytokinetics USD 24.26M 1.32M Jun/2025
GlaxoSmithKline 184M 22M Jun/2025
J&J USD 128M 9M Mar/2025
MacroGenics USD 802K 826K Jun/2025
Merck USD 305M 8M Jun/2025
Novartis USD 289M 19M Jun/2025
Pfizer USD 654M 0 Jun/2025
Regeneron Pharmaceuticals USD 3.6M 5.1M Jun/2025
Roche Holding CHF 311.5M 1000K Dec/2024
Xencor 8.24M 422K Jun/2025